WHY IT MATTERS: If endocannabinoid-targeted pharmaceuticals like these gain FDA approval, patients dealing with cancer-related weight loss and chemotherapy nerve pain could eventually have insurance-covered, standardized treatment options that work through the same system cannabis does. CLINICAL OVERVIEW: Artelo Biosciences is advancing pharmaceutical candidates that target the endocannabinoid system, including ART27.13 for cancer-related anorexia and ART26.12 for chemotherapy-induced peripheral neuropathy. These drug development programs represent a growing trend of biotech companies working to create FDA-approvable medications that modulate endocannabinoid pathways rather than relying solely on plant-derived cannabinoids.